Share on StockTwits

Agios Pharmaceuticals (NASDAQ:AGIO) SVP Glenn Goddard unloaded 10,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $46.30, for a total value of $463,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded down 1.36% on Wednesday, hitting $45.66. The stock had a trading volume of 383,648 shares. Agios Pharmaceuticals has a 52 week low of $15.77 and a 52 week high of $50.37. The stock’s 50-day moving average is $40.14 and its 200-day moving average is $39.93. The company’s market cap is $1.573 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings data on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.13. The company had revenue of $8.41 million for the quarter, compared to the consensus estimate of $11.00 million. During the same quarter in the previous year, the company posted ($2.80) earnings per share. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. Analysts expect that Agios Pharmaceuticals will post $-1.94 EPS for the current fiscal year.

A number of analysts have recently weighed in on AGIO shares. Analysts at Citigroup Inc. initiated coverage on shares of Agios Pharmaceuticals in a research note on Tuesday, July 1st. They set a “buy” rating and a $58.00 price target on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 16th. They now have a $60.00 price target on the stock, up previously from $55.00.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.